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Abstract
Background: Although the mitochondrial DNA (mtDNA) mutations m.1555A > G and m.3243A > G are the primary
causes of maternally inherited sensorineural hearing loss (SNHL), several other mtDNA mutations are also reported
to be associated with SNHL.
Methods: Screening of m.1555A > G and m.3243A > G mutations was performed for 145 probands. Nine probands
fulfilled the following criteria: 1) bilateral and symmetric SNHL, 2)≥ 4 family members with SNHL with a maternal
trait of inheritance in≥ 2 generations, 3) onset of SNHL before the age of 40 years, 4) high-frequency SNHL, and 5)
no record of environmental factors related to SNHL. Sequencing of additional mtDNA regions was performed for
five subjects meeting the clinical criteria, but the screening results were negative.
Results: Among the nine cases meeting the five clinical criteria detailed above, three had the m.1555A > G
mutation in MTRNR1, one had a m.3243A > G mutation in MTTL1, and one case had a m.7511T > C mutation in
MTTS1. In the family with the m.7511T > C mutation, penetrance of SNHL among maternally related subjects was
9/17 (53%). The age at onset varied from birth (congenital) to adulthood. Hearing levels varied from normal to
moderately impaired, unlike previously reported subjects with this mutation, where some maternal family members
presented with profound SNHL. Family members with the m.7511T > C mutation and SNHL did not exhibit any
specific clinical characteristics distinct from those of other individuals with SNHL and different mtDNA mutations.
Among the 136 probands who did not meet the criteria detailed above, one case had the m.1555A > G mutation,
and three cases had the m.3243A > G mutation.
Conclusions: Since five of nine probands with the clinical criteria used in this study had mtDNA mutations, these
criteria may be helpful for identification of candidate patients likely to have mtDNA mutations.
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Background
Hearing loss is one of the most prevalent sensory disor-
ders. Genetic factors are thought to account for more than
half of congenital and childhood-onset hearing loss [1, 2],
and mutations of mitochondrial DNA (mtDNA) are asso-
ciated with maternally inherited sensorineural hearing loss
(SNHL). Human mtDNA is a double-stranded, circular
molecule, encoding 13 protein subunits, two ribosomal
RNAs (rRNAs), and 22 transfer RNAs (tRNAs) [3].
Among the mutations in mitochondrial genes, m.1555A >
G in MTRNR1 (also known as 12SrRNA), and m.3243A >
G in MTTL1 (tRNALeu(UUR)) are relatively frequent causes
of SNHL [4]. The m.1555A >G mutation in MTRNR1 is
associated with aminoglycoside ototoxicity and nonsyn-
dromic SNHL, while MTTL1 m.3243A >G is associated
with mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS); maternally inherited
diabetes and deafness syndrome (MIDD); and chronic
progressive external ophthalmoplegia (CPEO). In addition,
several other mitochondrial mutations, including m.14
94C > T in MTRNR1, and m.7445A>G, 7472insC, and
7511T > C in MTTS1 (tRNASer(UCN)) have been associated
with nonsyndromic SNHL [4]. Furthermore, m.8344A>G
and m.8356T > C mutations in MTTK (tRNALys) [5], the
m.14709T > C mutation in MTTE (tRNAGlu) [6], and
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several variants in MTTH (tRNAHis) [7] and MTTS2
(tRNASer(AGY)) [8] have also been confirmed, or are
reported, as associated with nonsyndromic or syndromic
SNHL.
The clinical features of mitochondrial hearing loss are:
1) maternal inheritance; 2) hearing loss is always sensori-
neural and primarily symmetrical, with involvement of
the higher frequencies, or all frequencies; 3) variable
penetrance and severity, even within families; and 4) in
general, childhood onset (postlingually) [4].
In this study, we performed mtDNA mutation analysis
on two rRNA and 22 tRNA genes, including MTRNR1,
MTTL1, MTTS1, MTTK, MTTH, MTTS2, and MTTE,
variants in which have previously been reported to be
associated with SNHL. We also investigated the clinical
characteristics of family members with the m.7511A > C
mutation. We propose criteria to identify candidate pa-
tients likely to have mitochondrial mutations.
Methods
Subjects
The present study included 171 consecutive subjects
from 145 families who visited the Department of Oto-
laryngology at Keio University Hospital with complaints
of hearing loss and were then referred to the Center for
Medical Genetics for genetic evaluation. Based on the
clinical features of mitochondrial deafness (as reviewed
by Kokotas et al. [4]), patients were selected for compre-
hensive mtDNA analysis if they met the following clin-
ical criteria: 1) bilateral and symmetric SNHL; 2) at least
four family members with SNHL with a maternal trait of
inheritance for at least two generations; 3) onset of
SNHL before the age of 40 years; 4) high-frequency
SNHL (≥15 dB difference in hearing levels between the
means of 0.5 and 1 kHz and the means of 4 and 8 kHz,
assessed by pure-tone audiometry. Both “gently sloping”
and “steeply sloping” audiograms were taken into
account); and 5) no record of environmental factors
related to hearing loss, such as infectious diseases, pre-
mature birth, or newborn meningitis. The audiometric
configuration of criterion 4) and severity of hearing loss
were determined according to the guidelines of the
GENEDEAF study group (http://hereditaryhearingloss.org).
Patients with a history of use of ototoxic drugs were
included in this study, because some drugs are associated
with mitochondrial SNHL. Kaplan-Meier curves were
plotted using R platform.
Genetic analysis
Genomic DNA was extracted from blood samples using
the Gentra Puregene Blood kit (QIAGEN, Hamburg,
Germany). Detection of the m.1555A >G and m.3243A >
G mutations in all 145 probands was performed by restric-
tion fragment length polymorphism (RFLP) analysis, as
previously described [9, 10]. Samples from five subjects,
who met the clinical criteria and were not found to have
mtDNA mutations by RFLP, were subjected to mutation
analysis of mtDNA regions, including two rRNA and 22
tRNA genes by nested PCR, as described in [11] with
modification. The nested-PCR was performed using
PrimeSTAR HS DNA polymerase (Takara Bio, Shiga,
Japan) and the following program: 98 °C for 10 min; 37 cy-
cles of 98 °C for 10 s, 62 °C for 10 s, and 72 °C for 1 min;
and then 72 °C for 3 min. PCR primers are listed in
Additional file 1. Amplicons were sequenced using an ABI
3730 DNA sequence analyzer, using the ABI Prism Big
Dye Terminator Cycle Sequencing kit (Applied Biosys-
tems, MA, USA). Sequences were characterized using
SeqScape software v2.6 (Applied Biosystems) and DNASIS
Pro (Hitachisoft, Tokyo, Japan) with rCRS NC_012920.1.
Results
mtDNA analysis
Among 145 probands who visited the Department of
Otolaryngology at Keio University Hospital, nine fulfilled
the five clinical criteria detailed in the Methods section
and were, therefore, analyzed for mtDNA mutations.
Among these nine individuals, homoplasmic m.1555A >
G and heteroplasmic m.3243A > G mutations were iden-
tified in three cases and a single case, respectively by
RFLP analysis. Samples from the remaining five cases,
who met the clinical criteria but did not have
m.1555A > G or m.3243A > G mutations, were subjected
to Sanger sequencing analysis of mtDNA regions, in-
cluding two rRNA and 22 tRNA genes, as described in
the Methods section. One case had a homoplasmic (or a
high level heteroplasmic) m.7511T > C mutation in
MTTS1 (Fig. 1). Other mtDNA variants detected in the
five subjects are presented in Additional file 2. No novel
or possible pathological mutations, nor any unknown
variants, were detected in the remaining four subjects.
RFLP screening revealed homoplasmic m.1555A > G
and heteroplasmic m.3243A > G mutations in one and
three patients, respectively, among 136 probands who
failed to meet the five criteria. The clinical features of
Fig. 1 Electropherograms of part of the MTTS1 sequence. Sequence
from the proband (III-5, left; showing the m.7511T > C mutation)
and a control subject with normal hearing (right) are shown
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probands with the m.1555A > G and m.3243A > G
mutations are presented in Additional file 3.
Clinical findings in the family with the m.7511T > C
mutation
In the family of the proband (III-5) carrying the
m.7511T > C mutation, nine (I-2, II-3, II-8, III-1, III-3,
III-5, IV-2, IV-3, and IV-6) of 17 maternally related
members in four generations exhibited SNHL (Fig. 2).
Subjects II-1, II-2, II-5, and II-7 died before they reached
adulthood (≥20 y) for reasons other than illness. The
phenotypes of seven family members identified as carry-
ing the m.7511T > C mutation by genetic analysis are
presented in Table 1. Five subjects, III-3, III-5, IV-2, IV-
3, and IV-6, were confirmed to have SNHL by pure-tone
audiometry. The onset of SNHL was congenital in one
subject (IV-6), during childhood in six subjects (II-3, II-
8, III-1, III-3, IV-2, and IV-3), and there was adult onset
in one subject (III-5) (Table 1, Fig. 3). The severity of
SNHL ranged from moderate in three subjects (III-3,
III-5, and IV-3), to moderate or mild in each ear in one
subject (IV-6), and mild in one subject (IV-2), whereas
the other two subjects (III-7, IV-4) demonstrated normal
hearing levels. The audiometric configuration was flat in
one subject (IV-2), gently sloping in one ear and flat in
the other ear in one subject (III-3), sloping in two sub-
jects (III-5 and IV-3), and low-frequency SNHL was de-
tected in one subject (IV-6). Three subjects (III-3, III-5,
and IV-3) showed progression of SNHL, whereas the
hearing levels of the other subjects (III-7, IV-2, IV-4, and
IV-6) did not worsen. No subjects showed fluctuation of
hearing. A speech discrimination test was performed for
four subjects (III-3, III-5, IV-2, and IV-3) and distortion-
product otoacoustic emissions (DPOAE) were tested for
six subjects (III-3, III-5, III-7, IV-2, IV-3, and IV-4). The
speech discrimination test indicated that all subjects
had ≥ 90% discrimination, other than one, who had dis-
crimination of 85% in the left ear. DPOAE was abnormal
at all, or some, tested frequencies in all subjects. These
results are consistent with hearing loss caused by inner
ear disorders. In addition to SNHL, subjects III-3 and
III-5 exhibited vertigo and tinnitus, whereas the other
individuals carrying the m.7511T > C mutation did not
present with additional symptoms.
Discussion
Among 145 probands, nine were analyzed for mtDNA
gene mutations based on the presence of clinical features
of mitochondrial SNHL. Five of these individuals were
found to carry mutations (three cases with m.1555A > G,
one with m.3243A > G, and one with m.7511T > C).
These results are in agreement with previous studies
reporting that m.1555A > G and m.3243A > G are the
highest frequency mtDNA mutations associated with
SNHL, and that other SNHL-associated mtDNA muta-
tions occur much less frequently [4, 11]. These two most
common mutations were detected in only 3% (one case
of m.1555A > G and three cases of m.3243A > G) of the
136 probands who did not meet the clinical criteria.
These results suggest that the clinical criteria adopted in
this study are helpful for selection of candidate patients
with a high probability of carrying mtDNA mutations.
No known pathogenic mutations, or unknown variants,
were detected in the remaining mitochondrial rRNA and
tRNA genes, including MTTK, MTTH, MTTS2, and
MTTE, consistent with a previous report that MTTS1 is
the third most frequent mtDNA region (after
m.1555A > G in MTRNR1 and m.3243A > G in MTTL1)
where mutations affecting auditory function occur [12].
Recent advances in next-generation sequencing tech-
nologies have enabled the identification of multiple nu-
clear genes responsible for hearing loss [13–15].
However, it is technically challenging to investigate
mtDNA and nuclear DNA mutations simultaneously by
next-generation sequencing, since mitochondrial genes
are between two and three orders of magnitude more
abundant than nuclear genes in the cell [16, 17]. There-
fore, pre-diagnostic selection of patients with a high
Fig. 2 Pedigree of the family with the m.7511T > C mutation. Arrow indicates the proband. Subjects with horizontal bars above the symbols
underwent genetic and clinical analyses, including an audiogram. Filled symbols indicate affected subjects
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probability of mitochondrial SNHL should contribute to
the efficient analysis of mtDNA mutations.
At present, five MTTS1 variants, including m.7511T >C,
are confirmed as, or suspected to be, associated with non-
syndromic or syndromic SNHL [4]. MTTS1 m.7511T >C
has been identified in families with various ethnic back-
grounds, including African-American, French, and Japanese
(Table 2). The penetrance, severity, age of onset, and pro-
gression of SNHL across these families varies widely, mak-
ing prediction of the effects of this mutation based on the
clinical features of the patients difficult. The finding that
patients in the family identified in this study with a
homoplasmic, or highly heteroplasmic, m.7511T >C muta-
tion had phenotypes ranging from normal hearing to mod-
erate levels of SNHL is unique compared with previous
reports, where some maternal family members with homo-
plasmic and heteroplasmic m.7511T >C mutations exhib-
ited profound SNHL (Table 2). The level of hearing loss of
the proband (III-3) of the family with this mutation in the
present study has remained moderate over 30 years, imply-
ing that severe hearing loss is not likely to develop before
the onset of presbycusis in this family.
Among 17 maternally related individuals with the
m.7511T >C mutation in the present study, nine had
SNHL. However, the penetrance in this family (53%) should
be interpreted cautiously, because four subjects in gener-
ation II died before they reached adulthood. Considering
the possibility that SNHL had yet to occur in subjects II-1,
II-2, II-5, and II-7 at the time of their deaths, the actual
penetrance of SNHL in this family is presumably higher
than the calculated value. Consistent with this speculation,
the penetrance in subjects in generation III and later was 6/
9. Penetrance of SNHL in families with the m.7511T >C
mutation in previous studies varied from approximately 30
to 84% [18–22]. Varying severity and penetrance have also
been reported for m.1555A >G in MTRNR1 and
m.7445A >G in MTTS1, which are frequent mitochondrial
mutations associated with nonsyndromic SNHL [4, 23–29].
Future studies should investigate whether other mitochon-
drial DNA variants and/or haplotypes have modulatory
effects on penetrance or phenotype severity in families with
mtDNA mutations associated with SNHL.
Conclusion
Among the selected nine probands, five cases were
determined to have pathogenic mtDNA mutations (three
cases of m.1555A > G, one of m.3243A > G, and one
of m.7511T > C). The m.7511T > C mutation will be
Fig. 3 Onset age of hearing loss in family members with the
m.7511T > C mutation with a maternal pattern of inheritance.
Sixteen subjects in this pedigree were included in the Kaplan-Meier
analysis. Note that subject I-2 was not included in the analysis due
to insufficient clinical data. Vertical marks indicate censored subjects
Table 1 Clinical features of family members carrying the m.7511T > C mutation
Individual Sex Age of onset
(years)







III-3 F 13 42 Moderate/Moderate Gently sloping/Flat Yes 95%/85% Bilateral NR
III-5 F 35 41 Moderate/Moderate Gently sloping/
Gently sloping
Yes 90%/95% Bilateral NR
III-7 F – 39 Normal/Normal NA No Not tested R: NR except 1 kHz,
L: NR except 1 kHz
and 3 kHz
IV-2 F 7 7 Mild/Mild Flat/Flat No 100%/100% NR at 4 kHz
IV-3 F 5 9 Moderate/Moderate Steeply sloping/
Gently sloping
Yes 95%/90% Bilateral NR
IV-4 M – 22 Normal/Normal NA No Not tested Bilateral NR
IV-6 F 0 8 Mild/Moderate Low frequency/
Low frequency
No Not tested Not tested
R right ear, L left ear, NR no response, NA not applicable, DPOAE distortion-product otoacoustic emissions
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difficult to predict based on the variable clinical features
of the patients with this mutation. The clinical criteria
used in this study are considered helpful for the efficient
identification of patients likely to have mtDNA muta-
tions associated with SNHL.
Additional files
Additional file 1: Primers used in this study. (XLSX 11 kb)
Additional file 2: mtDNA variants detected in 5 probands fulfilling the 5
criteria. (XLSX 12 kb)
Additional file 3: Clinical features of probands carrying m.1555A > G or
m.3243A > G. (XLSX 11 kb)
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